Vistagen Therapeutics Inc (NASDAQ:VTGN) Director Jon S. Saxe bought 12,080 shares of the stock in a transaction that occurred on Wednesday, March 13th. The stock was bought at an average price of $1.26 per share, with a total value of $15,220.80. Following the completion of the purchase, the director now directly owns 3,251 shares in the company, valued at $4,096.26. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

NASDAQ VTGN traded down $0.01 on Friday, hitting $1.27. 495,452 shares of the company’s stock traded hands, compared to its average volume of 272,780. Vistagen Therapeutics Inc has a 1-year low of $0.81 and a 1-year high of $2.44. The stock has a market cap of $54.55 million, a price-to-earnings ratio of -1.14 and a beta of -0.34.

Vistagen Therapeutics (NASDAQ:VTGN) last announced its quarterly earnings data on Tuesday, February 12th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.02). Sell-side analysts forecast that Vistagen Therapeutics Inc will post -0.9 earnings per share for the current fiscal year.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Millennium Management LLC acquired a new stake in Vistagen Therapeutics during the 4th quarter valued at approximately $28,000. Northern Trust Corp lifted its stake in Vistagen Therapeutics by 168.6% during the 4th quarter. Northern Trust Corp now owns 69,642 shares of the company’s stock valued at $104,000 after acquiring an additional 43,714 shares during the period. D.A. Davidson & CO. lifted its stake in Vistagen Therapeutics by 22.9% during the 4th quarter. D.A. Davidson & CO. now owns 94,000 shares of the company’s stock valued at $141,000 after acquiring an additional 17,500 shares during the period. Geode Capital Management LLC lifted its stake in Vistagen Therapeutics by 13.0% during the 4th quarter. Geode Capital Management LLC now owns 154,457 shares of the company’s stock valued at $231,000 after acquiring an additional 17,721 shares during the period. Finally, Vanguard Group Inc lifted its stake in Vistagen Therapeutics by 42.7% during the 3rd quarter. Vanguard Group Inc now owns 257,465 shares of the company’s stock valued at $373,000 after acquiring an additional 77,090 shares during the period. Institutional investors and hedge funds own 9.97% of the company’s stock.

A number of research firms recently commented on VTGN. Maxim Group reiterated a “buy” rating and issued a $6.00 target price on shares of Vistagen Therapeutics in a research note on Wednesday, March 6th. ValuEngine cut shares of Vistagen Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, January 2nd. One analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $8.30.

WARNING: This article was reported by Marea Informative and is owned by of Marea Informative. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The original version of this article can be accessed at

About Vistagen Therapeutics

VistaGen Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for depression and other central nervous system (CNS) disorders. The company's lead product candidate is AV-101, which is in Phase II development stage, an adjunctive treatment used for major depressive disorder.

See Also: How Do You Calculate Return on Equity (ROE)?

Receive News & Ratings for Vistagen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vistagen Therapeutics and related companies with's FREE daily email newsletter.